A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer

被引:58
作者
Bahreini, Fatemeh [1 ]
Soltanian, Ali Reza [2 ]
Mehdipour, Parvin [1 ]
机构
[1] Univ Tehran Med Sci, Dept Med Genet, Sch Med, Tehran 1417613151, Iran
[2] Hamadan Univ Med Sci, Dept Biostat & Epidemiol, Modeling Noncommunicable Dis Res Ctr, Sch Publ Hlth, Hamadan 65155, Iran
关键词
HER2; Immunohistochemistry; Fluorescence in situ hybridization; Breast cancer; Meta-analysis; GROWTH-FACTOR RECEPTOR; TISSUE MICROARRAY; COST-EFFECTIVENESS; ESTROGEN-RECEPTOR; IMAGE-ANALYSIS; CORE BIOPSY; HER-2/NEU; EXPRESSION; AMPLIFICATION; ANTIBODIES;
D O I
10.1007/s12282-014-0528-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We performed this meta-analysis study to evaluate the concordance and discordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in detecting HER2 alteration in human breast cancer. Methods As a meta-analysis, the present study evaluated the available data from previous studies on the HER2 gene detected by IHC and FISH. To indicate the meta-analysis results, a forest plot was used. Results We identified 172 citations, for which our inclusion criteria were met by 18 articles, representing 6629 cases. The overall concordance and discordance rate between IHC staining with score 0/1+ and FISH for detection failure of HER2 expression was 96 and 4 %, respectively. The present study showed that the overall proportion of FISH positive and negative rate for IHC score 2+ for detection of HER2 expression was 36 and 64 %, respectively; and 91 and 9 % for 3+ IHC scores. Conclusion The results of this study show that IHC score 0/1+ and 3+ cannot be completely considered as negative and positive breast cancer test, respectively. Therefore, we suggest a valid and complementary test, the same as FISH, to explore HER2 expression.
引用
收藏
页码:615 / 625
页数:11
相关论文
共 97 条
  • [1] IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest™ in breast carcinoma
    Ainsworth, R
    Bartlett, JMS
    Going, JJ
    Mallon, EA
    Forsyth, A
    Richmond, J
    Angerson, W
    Watters, A
    Dunne, B
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (10) : 1086 - 1090
  • [2] Alkushi Abdulmohsen, 2009, Hematol Oncol Stem Cell Ther, V2, P394
  • [3] [Anonymous], ACTA HISTOC IN PRESS
  • [4] [Anonymous], BREAST CANC RES
  • [5] [Anonymous], AM J SURG PATHOL
  • [6] [Anonymous], 2009, AM J CLIN PATHOL, DOI DOI 10.1309/AJCPG3LCVKPNFJ6R
  • [7] [Anonymous], AM J SURG PATHOL
  • [8] [Anonymous], CANCER
  • [9] HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer
    Arens, N
    Bleyl, U
    Hildenbrand, R
    [J]. VIRCHOWS ARCHIV, 2005, 446 (05) : 489 - 496
  • [10] Protocolo de estudio molecular del oncogénHER2/neu en el carcinoma de mamaMolecular protocol forHER2/neu analysis in breast carcinoma
    Montse Verdú Artufel
    Anna Colomer Valero
    Ruth Román Lladó
    Nadina Erill Sagalés
    Miquel Calvo Llorca
    Abelardo Moreno Carazo
    Carlos Cordón Cardó
    Xavier Puig Torrus
    [J]. Clinical and Translational Oncology, 2005, 7 (11) : 504 - 511